frontline lenvatinib in hcc: study 304
Published 7 years ago • 927 plays • Length 6:06Download video MP4
Download video MP3
Similar videos
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
4:54
reflect trial: frontline lenvatinib’s value in hcc
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
4:16
frontline therapy for hcc: optimizing treatment selection
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
1:33
adverse events inform treatment decisions in hcc for frontline lenvatinib versus sorafenib
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
8:55
implication of upfront lenvatinib in hcc
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc
-
2:56
dr. finn on role of lenvatinib in hcc treatment paradigm
-
6:51
hcc: use of lenvatinib and sorafenib
-
4:41
hcc: evolution of frontline treatment
-
6:54
upfront lenvatinib in unresectable hcc
-
1:24
phase iii findings for lenvatinib in hcc
-
1:26
evaluating systemic therapies available for frontline treatment of hcc
-
7:38
frontline clinical trials in liver cancer
-
1:52
dr. bekaii-saab discusses the fda approval of lenvatinib in hcc